FLOW (trial)
The Phase 3 trials that won approval, and the outcome studies that came afterward on cardiovascular, kidney and sleep-apnea endpoints.
What is FLOW (trial)?
The first GLP-1 trial built around the kidney rather than the waistline.
Semaglutide 1 mg went up against placebo across 3,533 participants whose diabetes had already reached their kidneys (Perkovic 2024 NEJM, PMID 38785209). The kidney composite fell 24%, HR 0.76, and the study was halted early once the benefit was clear. That result drove the January 2025 Ozempic label expansion.
Related reading: FLOW: Semaglutide and the Kidneys
GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.
Where FLOW (trial) comes up on this site
On GLP Watchdog, FLOW comes up in 4 research articles and 1 tool.
Research that discusses it
Tools that use it
Other terms under Major trials
Where the evidence lives
- The full GLP-1 glossary (150 terms, 8 categories)
- Research articles — written from primary sources
- Tools and calculators
- Compare GLP-1 telehealth providers